JAGX Jaguar Health Inc.

2.1
-0.03  -1%
Previous Close 2.13
Open 2.13
52 Week Low 0.185
52 Week High 4.47
Market Cap $247,413,604
Shares 117,816,002
Float 117,621,069
Enterprise Value $294,183,086
Volume 7,733,493
Av. Daily Volume 65,237,606
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Crofelemer (Mytesi)
Chronic Idiopathic Diarrhea in Non-HIV Patients
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Mytesi (crofelemer)
Cancer Therapy-Related Diarrhea
Phase 3
Phase 3
Phase 3 trial initiation announced October 7, 2020.
Mytesi (crofelemer)
Inflammatory bowel disease (IBD)
Phase 2
Phase 2
Protocol development for discussions with FDA.

Latest News

  1. Site contains links to information about post-COVID-19 ‘long-hauler' syndrome

    An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients

    Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in long-hauler COVID-19 recovery patients in Europe

    SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched the website for Napo EU, the anticipated subsidiary of the Company in Italy. Click here to visit the website.

    The Resources…

    Site contains links to information about post-COVID-19 ‘long-hauler' syndrome

    An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients

    Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in long-hauler COVID-19 recovery patients in Europe

    SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched the website for Napo EU, the anticipated subsidiary of the Company in Italy. Click here to visit the website.

    The Resources page of the site contains links to an assortment of third-party information about post-COVID long-hauler syndrome, as well as the challenges posed in Europe and elsewhere by vaccine distribution programs, vaccine skepticism, and the appearance of more transmissible mutated strains of SARS-CoV-2, the virus that causes COVID-19.

    "Long-hauler syndrome has been generating a great deal of coverage over the past several months in major media around the globe," stated Lisa Conte, Jaguar's founder, president, and CEO. "In fact, yesterday an article titled "Terrifying 'post-COVID syndrome' is next focus for researchers in Bay Area and beyond" was published by the San Francisco Chronicle. The article references diarrhea as a symptom of long-hauler syndrome, and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients. We believe that GI symptoms in long-hauler patients may be related to inflammation, and thus analogous to GI symptoms observed in people who have lived with HIV/AIDS for a long period of time."

    Gut inflammation referred to as enteropathy is a chronic syndrome that has been observed in people who live with HIV/AIDS for long periods of time and is manifested as chronic diarrhea. Crofelemer (Mytesi®), Napo's commercialized antidiarrheal drug, is FDA-approved in the U.S. for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

    This past Friday, as also reported in the above-referenced the San Francisco Chronicle article, a University of Washington study published in the Journal of the American Medical Association found that 30% of 177 COVID patients reported symptoms up to 9 months after their illness. A link to the article appears on the Resources page of the Napo EU website. (Note that access to the article requires a subscription to the San Francisco Chronicle).

    The Company plans to add additional content to the website soon.

    As previously announced, the Company is exploring the conditional marketing authorization regulatory pathway in Europe to support development and commercialization of crofelemer for the proposed indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a long-hauler COVID-19 recovery patient population in Europe.

    The terms long-hauler and "chronic COVID" refer to COVID-19 survivors who suffer with symptoms which may include gastrointestinal distress (i.e., diarrhea, constipation, nausea, pain), fatigue, brain fog, forgetfulness, cardiovascular effects, and arthritis, for an extended period after recovery. It is theorized that these symptoms may result when the immune system in COVID-19 survivors continues to overreact even though the infection has passed.

    Mytesi (crofelemer delayed release tablets), the only oral plant-based prescription medicine approved under U.S. Food and Drug Administration (FDA) Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. Mytesi is a non-opiate chloride ion channel modulating antidiarrheal medicine that is approved in the U.S. by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

    About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

    For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

    About Mytesi®

    Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that additional content will be added to the Napo EU website soon, the belief that GI symptoms in long-hauler COVID patients may also be related to inflammation, and thus analogous to GI symptoms observed in people who have lived with HIV/AIDS for a long period of time, and the belief that crofelemer's mechanism of action has the potential to benefit multiple disorders. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Source: Jaguar Health, Inc.

    Contact:
    Peter Hodge
    Jaguar Health, Inc.

    Jaguar-JAGX

    SOURCE: Jaguar Health, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/631273/Jaguar-Health-Launches-Website-for-Napo-EU

    View Full Article Hide Full Article
  2. Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe

    SAN FRANSISCO, CA / ACCESSWIRE / February 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company is committed to moving forward with an exclusive relationship with the planned Dragon special purpose acquisition company (the "Dragon SPAC") and is supportive of the Dragon SPAC's intention for Napo EU, the anticipated subsidiary of the Company in Italy, to be the named target of the Dragon SPAC.

    As Jaguar announced yesterday, the Company has signed a Memorandum of Understanding (the "MOU") with Josh Mailman…

    Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe

    SAN FRANSISCO, CA / ACCESSWIRE / February 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company is committed to moving forward with an exclusive relationship with the planned Dragon special purpose acquisition company (the "Dragon SPAC") and is supportive of the Dragon SPAC's intention for Napo EU, the anticipated subsidiary of the Company in Italy, to be the named target of the Dragon SPAC.

    As Jaguar announced yesterday, the Company has signed a Memorandum of Understanding (the "MOU") with Josh Mailman, the lead sponsor of the Dragon SPAC, which is pursuing listing on AIM Italia.

    "Jaguar was previously in discussions with Andreea Porcelli, the founder and CEO of the planned Post Pandemic Recovery SPAC (the "PPR SPAC") regarding the listing of the PPR SPAC on AIM Italia and the potential merger of the PPR SPAC with Napo EU. However, we were not able to come to terms," stated Lisa Conte, Jaguar's founder, president, and CEO.

    "Although I was also unable to come to terms with Ms. Porcelli regarding the PPR SPAC, I am happy to move forward with the Dragon SPAC - and the proposed direct business combination with Napo EU - in the best interest of all parties," Mailman said. "I am the lead sponsor and providing funding for the proposed Dragon SPAC, and I am pleased to announce that we are in discussions with multiple global and Italian banks related to the anticipated listing of the Dragon SPAC on AIM Italia."

    Per the MOU, the Dragon SPAC has been granted exclusivity to negotiate and finalize the documentation for the contemplated merger transaction with Napo EU and to list the combined entity on AIM Italia.

    As previously announced, the Company is exploring the conditional marketing authorization regulatory pathway in Europe to support development and commercialization of crofelemer, the Company's novel proprietary drug, for the proposed indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a "long-hauler" COVID-19 recovery patient population in Europe (the "COVID-related indication"). The Company has engaged a regulatory agent in Europe and has a meeting organized with European regulatory authorities in March 2021.

    Mytesi (crofelemer delayed release tablets), the only oral plant-based prescription medicine approved under U.S. Food and Drug Administration (FDA) Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. Mytesi is a non-opiate chloride ion channel modulating antidiarrheal medicine that is approved in the U.S. by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

    About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

    For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

    About Mytesi®

    Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

    Forward-Looking Statements
    Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Napo EU will be the named target of the Dragon SPAC, the expectation that the Dragon SPAC will list on AIM Italia, and the belief that crofelemer's mechanism of action has the potential to benefit multiple disorders. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    CONTACT:
    Peter Hodge
    Jaguar Health, Inc.

    SOURCE: Jaguar Health, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/630801/Jaguar-Health-Announces-Commitment-to-Move-Forward-with-Exclusive-Relationship-with-the-Planned-Dragon-SPAC-which-is-Pursuing-Listing-on-AIM-Italia-and-Plans-to-Target-Napo-EU

    View Full Article Hide Full Article
  3. Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe

    SAN FRANCISCO, CA / ACCESSWIRE / February 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed a Memorandum of Understanding (the "MOU") with the lead sponsor of the planned Dragon special purpose acquisition company (the "Dragon SPAC"), which is pursuing listing on AIM Italia. Per the MOU, Napo EU, the anticipated subsidiary of the Company in Italy, will be the named target of the Dragon SPAC and has granted the Dragon SPAC exclusivity to list on AIM Italia and negotiate and finalize the documentation…

    Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe

    SAN FRANCISCO, CA / ACCESSWIRE / February 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed a Memorandum of Understanding (the "MOU") with the lead sponsor of the planned Dragon special purpose acquisition company (the "Dragon SPAC"), which is pursuing listing on AIM Italia. Per the MOU, Napo EU, the anticipated subsidiary of the Company in Italy, will be the named target of the Dragon SPAC and has granted the Dragon SPAC exclusivity to list on AIM Italia and negotiate and finalize the documentation for the contemplated merger transaction.

    The Dragon SPAC is a newly formed initiative expected to be incorporated in Italy, with lead sponsorship by Josh Mailman. A well-known, New York City-based impact investor, Mailman co-founded Social Venture Network (now Social Venture Circle) in 1987, founded the Threshold Foundation in 1981, and founded Business for Social Responsibility in 1992. He is also the managing director of Serious Change L.P., a $100 million privately held impact fund he started in 2006, serves on the boards of Benefithub, Giving Assistant, Baltix Design, and Red Rabbit, and is an advisor to Social Venture Circle and the Threshold Foundation.

    "We are so pleased to be working with the Dragon SPAC and an experienced leader like Josh Mailman. Josh is well-known for his integrity, and his investment values and skill set align with those of Jaguar, Napo, and Napo EU, and our mission," said Conte.

    "Napo's discovery efforts were founded 30 years ago to identify and develop novel plant-based drugs by leveraging the knowledge of traditional healers working in rainforest areas," Mailman stated. "The long-term commitment and leadership of the Jaguar and Napo management team, and their expertise in the development of crofelemer for GI distress, facilitated the rapid engagement that resulted in the signing of the MOU related to the anticipated merger of Napo EU with the Dragon SPAC. I am pleased that AIM Italia allows SPAC sponsors to name their intended target entity, and I believe that the novel, first-in-class mechanism of action of crofelemer (Mytesi®) - the Company's pioneering plant-based drug - may provide relief to COVID-19 long-hauler patients suffering from inflammatory diarrhea, just as crofelemer provides symptomatic relief of noninfectious diarrhea in adult patients in the U.S. with HIV/AIDS on antiretroviral therapy."

    As previously announced, the Company is exploring the conditional marketing authorization regulatory pathway in Europe to support development and commercialization of crofelemer, the Company's novel proprietary drug, for the proposed indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a "long-hauler" COVID-19 recovery patient population in Europe (the "COVID-related indication").

    "Napo EU will serve as the foundation of the Company's efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population," stated Lisa Conte, Jaguar's founder, president, and CEO. "Based on the MOU, we anticipate providing an exclusive license to Napo EU for the development, manufacture and commercialization of all planned crofelemer indications in Europe (excluding Russia), which rights and obligations shall be assumed by the combined company following a merger of Napo EU with the Dragon SPAC. The cornerstone of the license agreement will of course be the proposed COVID-related indication; however, the expected license will include all crofelemer pipeline indications of Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned U.S.-based subsidiary, with certain obligations to be met by Napo EU to maintain the license, indication by indication."

    Crofelemer (Mytesi), Napo's commercialized antidiarrheal drug FDA-approved in the U.S. for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, is in a pivotal Phase 3 clinical trial in the U.S. for the indication of cancer therapy-related diarrhea (CTD). In addition, Napo is supporting two investigator-initiated clinical studies of crofelemer in IBS/functional diarrhea in the U.S. and plans on studying congenital diarrheal disorders and short bowel syndrome, which are rare disease indications, using a novel crofelemer formulation.

    The terms "long-hauler" and "chronic COVID" refer to COVID-19 survivors who suffer with symptoms which may include gastrointestinal distress (i.e., diarrhea, constipation, nausea, pain), fatigue, brain fog, forgetfulness, cardiovascular effects, and arthritis, for an extended period after recovery. It is theorized that these symptoms may result when the immune system in COVID-19 survivors continues to overreact even though the infection has passed.

    It is estimated that as high as one-third1 of COVID-19-infected patients develop chronic or chronic episodic long-hauler syndrome - a constellation of post-viral infection symptoms. According to a November 1, 2020 Wall Street Journal article, the majority of the more than 300 long-COVID patients being seen at New York City's Mount Sinai Health System Center for Post-Covid Care appeared to have developed a dysautonomia-like condition, and about 40% to 50% of these patients also reported symptoms such as gastrointestinal issues, headaches and shortness of breath2. Based on these figures, the long-hauler population experiencing gastrointestinal distress could potentially range between 20 to 70 million people just in Europe.

    The Company is in the process of constructing the website for Napo EU, which will be located at www.napoeu.com. The site will serve as a source of information about long-hauler syndrome, as well as the challenges posed in Europe and elsewhere by vaccine distribution programs, vaccine skepticism, and the appearance of more transmissible mutated strains of SARS-CoV-2, the virus that causes COVID-19.

    Mytesi (crofelemer delayed release tablets), the only oral plant-based prescription medicine approved under U.S. Food and Drug Administration (FDA) Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. Mytesi is a non-opiate chloride ion channel modulating antidiarrheal medicine that is approved in the U.S. by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

    About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

    For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

    About Mytesi®

    Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Napo EU will be the named target of the Dragon SPAC, the expectation that the Dragon SPAC will be incorporated in Italy, the belief that the mechanism of action of crofelemer may provide relief to COVID-19 long-hauler patients suffering from inflammatory diarrhea, the expectation that an exclusive license will be provided to Napo EU for the development, manufacture and commercialization of all planned crofelemer indications in Europe, the belief that the long-hauler population experiencing gastrointestinal distress could potentially range between 20 to 70 million people just in Europe, and the belief that crofelemer's mechanism of action has the potential to benefit multiple disorders. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    1"Dr. Fauci Warns These COVID Symptoms Can Last for Months", Alex Korab, Newsbreak. https://www.newsbreak.com/news/2104072336660/dr-fauci-warns-these-covid-symptoms-can-last-for-months

    2"Doctors Begin to Crack Covid's Mysterious Long-Term Effects", Sarah Toy, Sumathi Reddy, Daniela Hernandez, Wall Street Journal, November 1, 2020. https://www.msn.com/en-us/health/health-news/doctors-begin-to-crack-covid-s-mysterious-long-term-effects/ar-BB1aAS6V

    Contact:

    Peter Hodge
    Jaguar Health, Inc.

    Jaguar-JAGX

    SOURCE: Jaguar Health, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/630448/Jaguar-Health-Signs-Memorandum-of-Understanding-with-the-Lead-Sponsor-of-the-Planned-Dragon-SPAC-Pursuing-Listing-on-AIM-Italia-Providing-the-Dragon-SPAC-with-Exclusivity-for-a-Proposed-Business-Combination-with-Napo-EU

    View Full Article Hide Full Article
  4. Team of advisors guides strategic research to discover and develop potential novel, natural psychoactive prescription medicines derived from Jaguar's library of 2,300 plants

    SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that noted natural products industry veteran Dr. Nigel Gericke has joined the scientific strategy team (SST) for the company's recently launched mental health Entheogen Therapeutics Initiative (ETI), which aims to discover and develop groundbreaking, novel, natural medicines derived from psychoactive plants for treatment of mood disorders, neurodegenerative diseases, addiction, and other mental health disorders. The SST consists of leading and globally renowned ethnobotanists…

    Team of advisors guides strategic research to discover and develop potential novel, natural psychoactive prescription medicines derived from Jaguar's library of 2,300 plants

    SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that noted natural products industry veteran Dr. Nigel Gericke has joined the scientific strategy team (SST) for the company's recently launched mental health Entheogen Therapeutics Initiative (ETI), which aims to discover and develop groundbreaking, novel, natural medicines derived from psychoactive plants for treatment of mood disorders, neurodegenerative diseases, addiction, and other mental health disorders. The SST consists of leading and globally renowned ethnobotanists, physicians, and pharmacologists, as well as experts in the fields of natural product chemistry and neuropharmacology.

    Dr. Gericke has spent more than 30 years involved in the discovery, innovation, clinical study, and commercialization of natural products and has extensive experience identifying, isolating, and characterizing active compounds and studying the molecular biology, pharmacology, and toxicology underpinning Indigenous plant use. He is a medical doctor, an ethnobotanist, and ethnopharmacologist, a former advisory panelist to the United States Pharmacopoeia (an independent, scientific nonprofit organization focused on building trust in the supply of safe, quality medicines), a longstanding member of the Medicinal Plants Specialist Group of the World Wide Fund For Nature, and a founding member of the Association for African Medicinal Plants Standards. Dr. Gericke is also a longtime advocate of ecological sustainability, social responsibility, and the need to recognize Indigenous rights.

    "We are thrilled and honored that Dr. Gericke - a highly respected veteran of the natural products industry - has joined the ETI scientific strategy team. We believe the wealth of expertise, experience, and commitment of our ETI SST - comprised of multiple members of the original scientific strategy team that contributed to development of Jaguar's proprietary library of approximately 2,300 plants - will play an instrumental role in advancing our shared initial goal of identifying plants in our library that may have the potential to treat mood disorders and neurodegenerative diseases, such as schizophrenia and other forms of psychosis, Alzheimer's disease, Parkinson's disease, and amyotrophic sclerosis," said Steven King, Ph.D., Jaguar's chief sustainable supply, ethnobotanical research and IP officer. Mood disorders and neurodegenerative diseases affect hundreds of millions of people around the globe and represent classic unmet medical needs.

    "I am delighted to have joined the ETI scientific strategy team and look forward to collaborating with the other team members as we work to discover novel therapies for managing mental health conditions from psychoactive plants that have been utilized by traditional healers for centuries. I believe psychedelic and psychoactive compounds derived from plants have significant potential for treating mental and neurological disorders and addressing other unmet mental health needs," said Dr. Gericke.

    The scientific strategy team for Jaguar's Entheogen Therapeutics Initiative is comprised of the following members:

    • Michael J. Balick, Ph.D.: Considered one of the world's leading ethnobotanists and economic botanists; specialist in healing plants and toxic plants and their use by Indigenous peoples; research associate of the Brain Chemistry Labs of the Institute of EthnoMedicine; member of original scientific strategy team that contributed to development of Jaguar's plant library.
    • Thomas Carlson, M.D., M.S.: Ethnobotanist, botanist, physician; teaching professor of integrative biology at the University of California, Berkeley; member of original scientific strategy team that contributed to development of Jaguar's plant library; key architect of ethnomedical field research process conducted by ethnobotanist/physician teams of Jaguar predecessor company Shaman Pharmaceuticals.
    • Pravin Chaturvedi, Ph.D.: Pharmacologist with specialty in neuropharmacology; chair of the Scientific Advisory Board of Napo Pharmaceuticals (Napo), Jaguar's wholly-owned subsidiary, and the acting chief scientific officer of Jaguar; Over 25+ year career, led discovery and/or development activities for several new chemical entities including development of Napo's FDA-approved drug product, Mytesi® (crofelemer), the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
    • Stephen Dahmer, M.D.: Ethnomedical researcher and practicing integrative physician; expert on endocannabinoids who has conducted ethnomedical field research in tropical regions.
    • Wade Davis, Ph.D.: Ethnobotanist, anthropologist, writer, and professor of anthropology at University of British Columbia; extensive international ethnobotanical field research.
    • Elaine Elisabetsky, Ph.D.: Among world's leading ethnopharmacologists; professor in the pharmacology and biochemistry departments of the Universidade Federal do Rio Grande do Sul in Brazil; member of original scientific strategy team that contributed to development of Jaguar's plant library.
    • Nigel Gericke, M.B.B.Ch.: Medical doctor, ethnobotanist, and ethnopharmacologist; former advisory panelist to the United States Pharmacopoeia; longstanding member of the Medicinal Plants Specialist Group of the World Wide Fund For Nature; founding member of the Association for African Medicinal Plants Standards.
    • Maurice Iwu, Ph.D.: President of Bioresources Development Group and founder of International Center for Ethnomedicine and Drug Development (InterCEDD) in Nigeria; member of original scientific strategy team that contributed to development of Jaguar's plant library.
    • Steven R. King, Ph.D.: Ethnobotanist; Napo's chief sustainable supply and ethnobotanical research officer; managed Napo's original scientific strategy team and outcomes; research associate of the Brain Chemistry Labs of the Institute of EthnoMedicine.
    • Charles Limbach, M.D.: Ethnomedical specialist and family medicine physician; member of original scientific strategy team that contributed to development of Jaguar's plant library.
    • David Sesin, Ph.D.: Natural product chemist; Jaguar's chief manufacturing officer; created isolation and manufacturing process for Mytesi (crofelemer).

    "Jaguar is thrilled to be leading this effort to potentially uncover a pipeline of novel psychoactive plant-based compounds, engage with recognized leaders in this space, and share our findings with potential corporate partners with the goal of developing plant-based compounds into possible medical breakthroughs," said Lisa Conte, Jaguar's president, and CEO. "While we remain steadfastly focused on the commercial success of Mytesi and on the development of crofelemer follow-on indications, we believe the same competencies and multi-disciplinary scientific strategy that led to the development of crofelemer will support collaborative efforts to discover and develop novel first-in-class prescription medicines derived from psychoactive plants."

    Crofelemer is in a pivotal Phase 3 trial in the U.S. for the indication of cancer therapy related-diarrhea and under development for diarrhea in a "long-hauler" COVID recovery patient population in Europe.

    About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

    Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

    For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

    About Mytesi®

    Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy, and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

    Forward-Looking Statements
    Certain statements in this press release constitute "forward-looking statements." These include statements related to the belief that the expertise, experience, and commitment of the ETI SST will play an instrumental role in advancing the initial goal of identifying plants in the company's plant library that may have the potential to treat mood disorders and neurodegenerative diseases, such as schizophrenia and other forms of psychosis, Alzheimer's disease, Parkinson's disease, and amyotrophic sclerosis, the belief that psychedelic and psychoactive compounds derived from plants have significant potential for treating mental and neurological disorders and addressing other unmet mental health needs, and the belief that the same competencies and multi-disciplinary scientific strategy that led to the development of crofelemer will support collaborative efforts to discover and develop novel first-in-class prescription medicines derived from psychoactive plants. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.

    CONTACT:
    Peter Hodge
    Jaguar Health, Inc.

    SOURCE: Jaguar Health, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/628409/Noted-Natural-Products-Industry-Veteran-Dr-Nigel-Gericke-Joins-Scientific-Strategy-Team-for-Jaguar-Healths-Recently-Launched-Mental-Health-Entheogen-Therapeutics-Initiative

    View Full Article Hide Full Article
  5. Webinar Title: The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health

    Webinar registration link appears below

    Over the last 30 years, the Jaguar team and partner organizations have substantially invested in developing the first and only oral plant-based prescription medicine approved under FDA Botanical Guidance while setting a standard for sustainable harvesting

    SAN FRANCISCO, CA / ACCESSWIRE / February 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Steven King, PhD, Jaguar's chief sustainable supply, ethnobotanical research and intellectual property officer, will discuss crofelemer development on February 4, 2021 from…

    Webinar Title: The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health

    Webinar registration link appears below

    Over the last 30 years, the Jaguar team and partner organizations have substantially invested in developing the first and only oral plant-based prescription medicine approved under FDA Botanical Guidance while setting a standard for sustainable harvesting

    SAN FRANCISCO, CA / ACCESSWIRE / February 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Steven King, PhD, Jaguar's chief sustainable supply, ethnobotanical research and intellectual property officer, will discuss crofelemer development on February 4, 2021 from 2 PM to 3 PM Eastern Time as part of the American Botanical Council's Sustainable Herbs Program webinar series. This ongoing webinar series features online conversations about key issues around sustainability and the botanical industry with leaders in the botanical community.

    Crofelemer, the active ingredient in Mytesi®, the FDA-approved drug product of Jaguar's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Crofelemer is also in a pivotal Phase 3 trial in the U.S. for the indication of cancer therapy related-diarrhea and under development for diarrhea in a long-hauler COVID recovery patient population in Europe. The title of the February 4th webinar is The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health. The registration link for this free online event appears below.

    Webinar Participation Instructions

    When: Thursday, February 4, 2021, 2-3 PM Eastern Time

    Registration Link: Click Here

    During the webinar, Dr. King will discuss the long-term sustainable harvesting program for Croton lechleri (Euphorbiaceae) that he and his colleagues in several Andean countries developed in collaboration with local and Indigenous communities and regional scientists, and review the ongoing efforts of the Jaguar and Napo teams to work with international partners and Indigenous and local communities to conserve biological diversity, recognize intellectual property rights, and meet global human health care needs. Dr. King is an ethnobotanist who has conducted field research on the use of plants for food and medicine in the highland and lowland regions of South America, Africa and parts of Southeast Asia over the past 42 years. He holds a PhD in biology with a focus on ethnobotany and economic botany.

    "I am very grateful to the Sustainable Herbs Program and the American Botanical Council for the opportunity to take part in this wonderful webinar series," stated King. "I in turn would like to specifically acknowledge the intellectual contribution of local and Indigenous peoples of the Northwest Amazon Basin for identifying the healing properties of traditional plant medicines. We would like to be sure that the international medical and patient community know that Indigenous science and ethnomedical expertise continues to provide solutions to medical challenges for humans and animals."

    As announced in February 2020, the American Botanical Council named Napo the recipient of the 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award.

    About the American Botanical Council
    Established in 1988, the American Botanical Council (ABC) is the leading independent, nonprofit, international member-based organization providing education using science-based and traditional information to promote the responsible use of herbal medicine. ABC serves the public, researchers, educators, healthcare professionals, industry and media, and has been a highly respected source and an innovative force for many years.

    The mission of ABC's Sustainable Herbs Program is to create a movement supporting high quality herbal products, sustainable and ethical sourcing, and greater overall transparency in how herbs reach end users. ABC works to achieve this by educating end-users and industry about the issues involved and by sharing best practices to inspire more companies to implement higher standards of sustainability.

    About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

    For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

    About Mytesi®
    Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

    Forward-Looking Statements
    Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that Dr. King will take part in the ABC webinar on February 4, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Contact:
    Peter Hodge
    Jaguar Health, Inc.

    Jaguar - JAGX

    SOURCE: Jaguar Health, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/627522/Jaguar-Healths-Chief-of-Sustainable-Supply-Dr-Steven-King-an-Ethnobotanist-to-Discuss-Crofelemer-Development-on-February-4th-at-2-PM-Eastern-as-Part-of-the-American-Botanical-Councils-Sustainable-Herbs-Program-Webinar-Series

    View Full Article Hide Full Article
View All Jaguar Health Inc. News